In This Article:
NEW YORK, NY / ACCESSWIRE / September 12, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against CV Sciences, Inc. (''CV Sciences'' or the ''Company'') (CVSI) and certain of its officers. The class action, filed in United States District Court, District of Nevada, and index under 18-cv-01709, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired CV Sciences securities between June 19, 2017 and August 20, 2018, both dates inclusive (the ''Class Period''), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the ''Exchange Act'') and Rule 10b-5 promulgated thereunder, against CV Sciences and certain of its top officials.
If you are a shareholder who purchased CV Sciences securities between July 19, 2017, and August 20, 2018, both dates inclusive, you have until October 23, 2018, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
[Click here to join this class action]
CV Sciences purports to operate as a life sciences company. It represents that it has two business divisions: Specialty Pharmaceuticals and Consumer Products. Its Specialty Pharmaceuticals division develops ''synthetically-formulated cannabidiol-based medicine,'' while the Consumer Products division ''delivers botanical-based cannabidiol products that enhance quality of life.'' CV Sciences was founded in 2010 and is headquartered in Las Vegas, Nevada. Its common stock trades over-the-counter (''OTC'') under the ticker symbol ''CVSI''.
The Company's chief pharmaceutical product is identified as CVSI-007, a chewing gum product that combines cannabidiol and nicotine in treatment of smokeless tobacco use and addiction. The Company described CVSI-007 to the public as its ''lead drug candidate'' with a market that has been estimated at ''greater than $2 billion,'' providing an important growth channel for CV Sciences.
On May 16, 2016, CV Sciences filed a patent application with the US Patent Trademark Office (''USPTO'') for CVSI-007, titled ''Pharmaceutical Formulations Containing Cannabidiol and Nicotine For Treating Smokeless Tobacco Addiction.'' On February 7, 2017, CV Sciences filed a continuing patent application under the same title, Patent #15/426,617 (the ''Patent'').